Trial Profile
A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of the Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2013
Price :
$35
*
At a glance
- Drugs Gevokizumab (Primary)
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Therapeutic Use
- 03 Sep 2013 Results presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.
- 23 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
- 03 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.